Hematopoiesis News Volume 12.38 | Sep 28 2021

    0
    56







    2021-09-28 | HN 12.38


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.38 – 28 September, 2021
    TOP STORY

    Mutational Synergy during Leukemia Induction Remodels Chromatin Accessibility, Histone Modifications and Three-Dimensional DNA Topology to Alter Gene Expression

    Researchers applied an integrated genomic approach to a murine allelic series that modeled the two most common mutations in acute myeloid leukemia (AML): Flt3-ITD and Npm1c, then deconvoluted the contribution of each mutation to alterations of the epigenetic landscape and genome organization.
    [Nature Genetics]

    Abstract

    Explore scientific events this October with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    tiRNA Signaling via Stress-Regulated Vesicle Transfer in the Hematopoietic Niche

    Scientists demonstrated that osteoblastic cells in the bone marrow niche elaborated extracellular vesicles (EV) that were taken up by hematopoietic progenitor cells in vivo, and that upregulating EV transfer improved hematopoietic recovery from genotoxic injury and survival from fungal sepsis.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    The Megakaryocytic Transcription Factor ARID3A Suppresses Leukemia Pathogenesis

    The authors reported that post-transcriptional repression of the transcription factor ARID3A by miR-125b was a key event in megakaryoblastic leukemia pathogenesis, and showed that chromosome 21-encoded miR-125b synergized with Gata1s to drive leukemogenesis in this context.
    [Blood]

    AbstractFull Article

    Super-Enhancer Landscape Reveals Leukemia Stem Cell Reliance on X-box Binding Protein 1 as a Therapeutic Vulnerability

    Disruption of the super-enhancer-associated gene transcription by THZ1, a covalent cyclin-dependent kinase 7 inhibitor, efficiently eradicated leukemia stem cells in retroviral BCR-ABL–driven chronic myelogenous leukemia mice while sparing normal hematopoietic stem cells.
    [Science Translational Medicine]

    Abstract

    The Oncomicropeptide APPLE Promotes Hematopoietic Malignancy by Enhancing Translation Initiation

    By combining Ribo-seq, mass spectrometry, and RNA-seq datasets, investigators discovered an oncomicropeptide, APPLE (a peptide located in ER), encoded by a non-coding RNA transcript in acute myeloid leukemia.
    [Molecular Cell]

    AbstractGraphical Abstract

    UFMylation of MRE11 Is Essential for Telomere Length Maintenance and Hematopoietic Stem Cell Survival

    Researchers generated zebrafish models deficient in Ufm1 and Ufl1 that exhibited telomere shortening associated with developmental delay, impaired hematopoiesis and premature aging.
    [Science Advances]

    Full Article

    Targeting the Actin Nucleation Promoting Factor WASp Provides a Therapeutic Approach for Hematopoietic Malignancies

    Since Wiskott–Aldrich Syndrome protein (WASp) is exclusively expressed in hematopoietic cells, scientists performed in silico screening to identify small molecule compounds that bound WASp and promoted its degradation.
    [Nature Communications]

    Full Article

    U2af1 Is a Haplo-Essential Gene Required for Hematopoietic Cancer Cell Survival in Mice

    Investigators showed that hematopoiesis and RNA splicing in U2af1 heterozygous knock-out mice was similar to control mice, but that deletion of the wild-type allele in U2AF1 heterozygous mutant expressing hematopoietic cells was lethal.
    [Journal of Clinical Investigation]

    AbstractFull ArticleGraphical Abstract

    Culturing Patient-Derived Malignant Hematopoietic Stem Cells in Engineered and Fully Humanized 3D Niches

    Human malignant cells distributed in the bioreactor system mimicking the spatial distribution found in native bone marrow tissue, where most hematopoietic stem and progenitor cells remained linked to the niches and mature cells were released to the circulation.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Spred1 Deficit Promotes Treatment Resistance and Transformation of Chronic Phase CML

    Spred1 knockout, regardless if occurred in HSCs or in endothelial cells, increased miR-126 in Lin−Sca-1+c-Kit+, a population enriched in leukemic stem cells (LSCs), resulting in expansion of LSCs, likely through hyperactivation of the MAPK/ERK pathway that augmented Bcl-2 expression and stability.
    [Leukemia]

    AbstractGraphical Abstract

    Phase I/II Study of Uproleselan Added to Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia

    A Phase I/II study evaluated the safety, tolerability, and anti-leukemic activity of uproleselan with mitoxantrone, etoposide, and cytarabine among patients with relapsed/refractory acute myeloid leukemia.
    [Blood]

    Abstract

    Delayed Administration of Ixazomib Modifies the Immune Response and Prevents Chronic Graft-versus-Host Disease

    Researchers aimed to modify the immune response in the long term after allogeneic bone marrow transplantation by using the proteasome inhibitor ixazomib at the late stages of the post-transplant period.
    [Bone Marrow Transplantation]

    Full Article

    Peritransplant Ruxolitinib Administration Is Safe and Effective in Patients with Myelofibrosis: A Pilot Open-Label Study

    Scientists reported results of a prospective pilot trial evaluating the safety/feasibility of peri-transplant administration of ruxolitinib for myelofibrosis treatment. Peri-HCT ruxolitinib was safe and well-tolerated with the maximum tolerated dose determined as 10 mg BID, associated with dose-dependent PK and cytokine profile.
    [Blood Advances]

    Abstract

    Image of erythroblasts which were simply & efficiently generated from PSCs using the STEMdiff Erythroid Kit.
    REVIEWS

    Mitochondrial Metabolism as a Potential Therapeutic Target in Myeloid Leukemia

    Investigators present a detailed overview of the most recent studies that present experimental evidence on how leukemic cells can metabolically rewire, more specifically the importance of OXPHOS in leukemic stem cells and treatment-resistant cells, and the current drugs available to target this process.
    [Leukemia]

    Full Article

    Phenotypic Plasticity of Myeloid Cells in Glioblastoma Development, Progression, and Therapeutics

    The authors revisit biological characteristics and functions of infiltrating myeloid cells and discuss the recent advances in immunotherapies targeting infiltrating myeloid cells in glioblastoma .
    [Oncogene]

    Full Article

    Long Noncoding RNAs: A Novel Insight in the Leukemogenesis and Drug Resistance in Acute Myeloid Leukemia

    Scientists discuss the significant role of long non-coding RNAs in the proliferation, survival, differentiation, leukemic stem cells in acute myeloid leukemia and their involvement in different molecular pathways
    [Journal of Cellular Physiology]

    Abstract

    INDUSTRY AND POLICY NEWS

    JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

    JW Therapeutics announced that it has received the Investigational New Drug clearance from the National Medical Products Administration of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor T cell JWCAR129 in treating relapsed or refractory multiple myeloma.
    [JW Therapeutics]

    Press Release

    AB Science Receives Health Canada Approval Letter to Commence Phase I/II Trial of AB8939 in the Treatment of Acute Myeloid Leukemia (AML)

    AB Science SA announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada. The company will proceed with a Phase I/II study in patients with refractory and relapsed AML and refractory myelodysplastic syndrome.
    [AB Science SA (Globe Newswire, Inc.)]

    Press Release

    bluebird bio Submits Biologics License Application (BLA) to FDA for Betibeglogene Autotemcel (Beti-Cel) Gene Therapy for Patients with β-Thalassemia Who Require Regular Red Blood Cell Transfusions

    bluebird bio, Inc. announced it has completed the rolling submission of its BLA to the US FDA for beti-cel gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell transfusions, across all genotypes.
    [bluebird bio, Inc.]

    Press Release

    FEATURED EVENT

    AACR Virtual Meeting: Precision Medicine Strategies to Improve Therapy of Diffuse Large B-Cell Lymphoma

    September 30 – October 1, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Faculty and Leadership Positions – Cancer-Focused Target and Drug Discovery

    The University of New Mexico – Albuquerque, New Mexico, United States

    PhD Scientists – Tumor Immune Microenvironment

    Moores Cancer Center, UC San Diego – San Diego, California, United States

    Head of Laboratory – Cellular Therapies

    NHS Blood and Transplant – Oxford, England, United Kingdom

    Senior Scientist – Gene Editing

    Cellectis – Paris, France

    Postdoctoral Position – Cancer Biology

    Houston Methodist Research Institute – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter